Posted by Michael Wonder on 21 Dec 2022
Idorsia submits a new drug application to the US FDA for aprocitentan for the treatment of patients with difficult to control hypertension
20 December 2022 - The application includes data from the Phase 3 registration trial of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well tolerated.
Idorsia today announced that it has submitted a new drug application to the US FDA seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult to control hypertension.
